User Comments Most Liked Latest
Login to join the conversation.
Reddit Mentions Today Week Month
GANX touching $3.999 now, slow and steady and great support/resistance testing. Still a speculative play but think this goes large as more data comes out
GANX going brrrrr
Anyone else in GANX??
GT-02287 addresses multiple potential sources of Parkinson's ($GANX)
Careful about this one. Always check post history of commenters for GANX and you will find tons of bot accounts posting nothing about this stock.
Have a look at GANX. Not saying buy for the sake of buying, but look it up
Here is latest info including H.C. Wainwright update. Very interesting comments by him. Gain Therapeutics(GANX): Updated Analyst Reports with All Eyes on Biomarker readout in Q4 https://gaintherapeutics.wordpress.com/2025/11/16/gain-therapeuticsganx-updated-analyst-reports-with-all-eyes-on-biomarker-readout-in-q4/
GT-02287 addresses multiple potential sources of Parkinson's ($GANX) What’s the first domino in Parkinson’s disease? **Mainstream science points to the lysosome and α-synuclein aggregation—the idea that misfolded α-syn builds up because the lysosomal “trash system” breaks down. But what if that’s not where the problem starts?** The recent Neuroscience poster …
Just opened a position on GANX.
Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days
Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days
Don't miss out on GANX. Im in at 2.85
GANX. Cure/slow for Parkinson’s This is critical: GANX will not move gradually — it will move in violent jumps on news. Q1–Q2 2025 Phase 1b biomarker + functional interim data • Likely price reaction: +20% to +150% if strong • Or –20% to –50% if poor Q3–Q4 2025 Full Phase …
GANX is in the move. Going from 3.60 to 60$+ in next year. Parkinson’s cure.
Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days
Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days Gain Therapeutics will put out their 90 day phase 1b Parkinson’s trial data this month. This data will have 16 patients through the first 90 days of the trial. It will include biomarker data …
GANX December Updated Corporate Deck Getting one last GANX post in before the company rockets out of Pennystock land. I linked the new corporate slide deck. Note in slide 3 the bullet about GT-02287 that reads: “Initial results from Phase 1B suggest GT-02287 has a disease-slowing effect” That bullet statement …
GANX gonna graduate from Pennyland soon
GANX
Janx went down over 50% yesterday on news of some delays. Analysts say it was an overreaction, stock is barely outside of penny territory. Also GANX might pop, there s serious dd on it if you guys want to look
GANX break-out attempt
GANX only not breaking due to ATM-offering; that stock is coiling
GANX breakout brewing
GANX GANX GANX Expanded my position by 300%
GANX is rising on high volume, despite being 3 days after ATM-offering stock is up 8% trading on 80% volume compared to first day after ATM-offering was announced Catalyst (potentially first parkinsons decease modifying drug; phase 1b data announcement) in the coming weeks Current cap: 117M, this could explode I …
GANX might be leaving the station Data on potentially decease modifying parkinsons drug set to be announced in the coming weeks ATM-offering announced this weekend, stock dipped to 3; Has now recovered to VWAP of yesterday (>3.20), trading at >80% (!!) volume compared to first day after ATM-offering news Current …
GANX might be leaving the station Data on potentially decease modifying parkinsons drug set to be announced in the coming weeks ATM-offering announced this weekend, stock dipped to 3; Has now recovered to VWAP of yesterday (>3.20), trading at >80% (!!) volume compared to first day after ATM-offering news Current …
Dipped below 3 today, recovery to VWAP of yesterday, trading at >80% volume compared to first day after ATM-offering was announced; the GANX train might be leaving the station With data announcement imminent (1/2 weeks?)
Gain Therapeutics ($GANX) — quietly emerging as one of the most compelling Parkinson’s stories in biotech.
Gain Therapeutics ($GANX) — quietly emerging as one of the most compelling Parkinson’s stories in biotech. **The set-up that Gain Therapeutics has right now is extremely rare, IMO. Largely de-risked, and is only a week or two away from releasing what is likely some of the most compelling evidence of …
GANX (Big catalyst coming) and ETHZ ❤️
GANX
GANX
GANX Gain Therapeutics with December Parkinson’s Data
GANX
ETHZ and GANX 🙌🏻
GANX and ETHZ 🥳
GANX and ETHZ
GANX
GANX biomarker data to be announced this december, put a stop loss and hope for the best!
GANX
Gain Therapeutics $GANX Analyst Report highlights 3 unique Parkinson’s Models showing Mitochondrial Benefits
Gain Therapeutics $GANX Analyst Report highlights 3 unique Parkinson’s Models showing Mitochondrial Benefits A recent analyst report by H.C. Wainwright points out the significance of the most recent Neuroscience poster that Gain published recently. Many different studies have recently highlighted that mitochondrial health is tightly tied to the development of …
$GANX shows return of smell in Parkinson’s patients - Major December catalysts ahead
$GANX shows return of smell in Parkinson’s patients - Major December catalysts ahead For Gain Therapeutics 2025 has been a very busy year and as 2025 winds down the best is yet to come. In 2025 Gain has reported both Phase 1a and 1b data on their Parkinson’s disease modifying …
GANX! Look at their progress
GANX … interim data and company remarks point to improved motor function and return of sense of smell in Parkinson’s patients in 90 days. Full data readout in the next couple of weeks likely to establish GT-02287 as the most promising treatment for Parkinson’s disease, and the first disease modifying …
More $GANX https://preview.redd.it/hy00c1vpvk4g1.jpeg?width=1080&format=pjpg&auto=webp&s=6847d0ead7f6f1547d005d826d61ac64a51b2877
Holding GANX and waiting for biomarker data this december!
GANX
GANX Gain Therapeutics with December Parkinson’s Data
My Swan Song: How 20 Years of Grinding Led Me to $GANX
GANX, ARWR
Thanks. Great info. Truth is, it’s only a matter of days or weeks until the biomarker data is out. Potentially Life changing in many ways. Once people do their DD, I’m sure they’ll see there’s not many stocks that impress more than $GANX whether your outlook is short term, or …
I added the data chart. People will want to see it. Gain Therapeutics(GANX): Updated Analyst Reports with All Eyes on Biomarker readout in Q4 https://gaintherapeutics.wordpress.com/2025/11/16/gain-therapeuticsganx-updated-analyst-reports-with-all-eyes-on-biomarker-readout-in-q4/
GANX Gain Therapeutics with December Parkinson’s Data There have been multiple recent posts on Gain Therapeutics and that they will be releasing in December additional Phase 1b data. So far from the Phase 1b 90 day trial of 16 patients we have seen UPDRS scores on 9 of them. These …
GANX is NOT a meme or pump stock its a solid grower with high M&A potential my group is very bullish on it 10-12 mths for buyout is our target
GANX is a great move. Soon to release Parkinson’s disease cure info soon
GANX
Related News
No related news found for this ticker.
Badges / Notes
- No notable badges.
Total Off-Exchange Volume: 1.4 million
Values over 50% Short often indicate hidden bearish pressure from institutions.
🏆 Master Buzz Score: 3/15
Capitol Trades
| Date | Politician | Amount |
|---|---|---|
| No recent trades found. | ||
Insider Trades
| Date | Insider | Value |
|---|---|---|
| No recent trades found. | ||
Institutional Holdings (Whales)
| Institution | Shares | Value | % Held | Date |
|---|---|---|---|---|
| Jones Financial Companies, L.L.L.P. | 676,822 | $2.4 million | 0.0187% | Sep 30, 2025 |
| DME Capital Management, LP | 566,130 | $2.0 million | 0.0156% | Sep 30, 2025 |
| Vanguard Group Inc | 534,352 | $1.9 million | 0.0147% | Sep 30, 2025 |
| Citadel Advisors Llc | 373,558 | $1.3 million | 0.0103% | Sep 30, 2025 |
| Geode Capital Management, LLC | 344,146 | $1.2 million | 0.0095% | Sep 30, 2025 |
| Cambridge Investment Research Advisors Inc. | 318,645 | $1.1 million | 0.0088% | Sep 30, 2025 |
| Marshall Wace LLP | 175,107 | $612874 | 0.0048% | Sep 30, 2025 |
| Morgan Stanley | 155,675 | $544862 | 0.0043% | Sep 30, 2025 |
| UBS Group AG | 140,677 | $492369 | 0.0039% | Sep 30, 2025 |
| Renaissance Technologies, LLC | 126,100 | $441350 | 0.0035% | Sep 30, 2025 |

No comments yet. Be the first!